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Abstract
There is widespread evidence that dopamine is implicated in the regulation of reward and salience. However, it is less known
how these processes interact with attention and recognition memory. To explore this question, we used the attentional boost test
in patients with Parkinson’s disease (PD) before and after the administration of dopaminergic medications. Participants performed
a visual letter detection task (remembering rewarded target letters and ignoring distractor letters) while also viewing a series of
photos of natural and urban scenes in the background of the letters. The aim of the game was to retrieve the target letter after
each trial and to win as much virtual money as possible. The recognition of background scenes was not rewarded. We enrolled
26 drug-na€ıve, newly diagnosed patients with PD and 25 healthy controls who were evaluated at baseline and follow-up. Patients
with PD received dopamine agonists (pramipexole, ropinirole, rotigotine) during the 12-week follow-up period. At baseline, we
found intact attentional boost in patients with PD: they were able to recognize target-associated scenes similarly to controls. At
follow-up, patients with PD outperformed controls for both target- and distractor-associated scenes, but not when scenes were
presented without letters. The alerting, orienting and executive components of attention were intact in PD. Enhanced attentional
boost was replicated in a smaller group of patients with PD (n = 15) receiving L-3,4-dihydroxyphenylalanine (L-DOPA). These
results suggest that dopaminergic medications facilitate attentional boost for background information regardless of whether the
central task (letter detection) is rewarded or not.
Introduction
There is a debate on the role of the midbrain dopaminergic centers
in the regulation of motivation, salience processing and reward
(Robbins & Everitt, 2007; Berridge, 2007, 2012). A leading theory
is that dopamine enhances reinforcement learning, resulting in the
successful selection of rewarding actions during trial-and-error
instrumental learning (Montague et al., 1996; Schultz et al., 1997;
Samejima et al., 2005). Recent evidence suggests that reward may
speciﬁcally modulate perception and memory. Seitz et al. (2009)
presented visual orientation stimuli to thirsty individuals. Stimuli
were paired with water administration as a reward. The authors
demonstrated that visual learning was facilitated by stimulus–reward
pairing without awareness of stimulus exposure and reward contin-
gency (Seitz et al., 2009). Incidental learning elicited by reward sig-
nals may be linked to attentional modulation. When participants pair
a target stimulus with reward, it may lead to attentional allocation
and better memory encoding not only for the target stimulus, but
also on a non-relevant concurrently performed task (task-irrelevant
perceptual learning; Seitz & Watanabe, 2009).
Lin et al. (2010) designed a task in which central white letters were
the targets to be remembered. Participants also viewed a series of pho-
tos of natural and urban scenes in the background of the letters. When
there was no letter detection task, memory for scenes was at chance
level. In contrast, when participants detected target letters, they also
performed remarkably well on the recognition of background scenes.
Distractor letters with another color that should be omitted did not
encourage scene recognition (Fig. 1). The enhancement of background
information (scenes) at behaviorally relevant points of time (i.e. when
target letters are available) is also called the attentional boost effect
(Swallow & Jiang, 2010, 2011). A possible interpretation is that target
letters elicited salient reward signals because the main aim of the task
was their later recall. This signal may ‘open’ the attentional window
leading to the incidental encoding of the background scene.
Ample evidence suggests that dopamine is implicated in attention
regulation, and dopaminergic mechanisms may link salience/reward
and attention (Nieoullon, 2002). For example, drugs enhancing
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dopaminergic transmission facilitate visual attention and memory via
the modulation of the dorsal fronto-parietal attentional network
(M€uller et al., 2005; Tomasi et al., 2011), which is responsible for
enhancing salient and attenuating irrelevant stimuli (Corbetta &
Shulman, 2002). Dopamine may play a vital role in the balanced and
adaptive activation of functionally separated attentional networks of
alerting, orienting and executive functions (Dang et al., 2012).
Parkinson’s disease (PD) is characterized by the degeneration of
dopaminergic neurons in the mesencephalon, resulting in various
deﬁcits in motor control, motivation and reinforcement learning,
which is modulated by dopamine replacement therapy [dopamine
precursor L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine
receptor agonists; reviewed in Frank, 2005; Cools, 2006; Foerde &
Shohamy, 2011]. Some studies revealed attentional impairments in
both early and advanced PD (e.g. Brown & Marsden, 1988; Yamada
et al., 1990; Hodgson et al., 1999; Muslimovic et al., 2005; Allcock
et al., 2009; Zhou et al., 2012), whereas others did not do so (e.g.
Rafal et al., 1984; Lee et al., 1999; Kingstone et al., 2002; Cris-
tinzio et al., 2012). Dopaminergic signals in the striatum and its
interaction with the prefrontal cortex would be especially critical in
the regulation and integration of higher-level processes, such as
attention and cognitive control (Cools, 2011).
The ﬁrst aim of the present study was to examine how dopamine
participates in the regulation of attentional boost by the investigation
of patients with PD before and after the administration of dopaminer-
gic medications. We hypothesized that patients with PD receiving
dopamine agonists would improve scene recognition performance
when scenes are presented with rewarded target letters. Second, we
studied the relationship between attentional boost and traditional
components of attention (alerting, orienting, executive). Third, we
explored the relationship between changes in clinical symptom and
psychological trait (motor symptoms, depression, impulsivity) and
attentional boost before and after dopamine agonist therapy. Finally,
we assessed a separate group of patients with PD receiving L-DOPA
medication to test the reproducibility of the results and to examine
whether the observed effects are speciﬁc for dopamine agonists or not.
Materials and methods
Participants
In the ﬁrst sample, we recruited 26 newly diagnosed, drug-naive
patients with PD and 25 control individuals (acquaintances of hospital
staff and non-biological family members of patients matched for age,
gender, education and IQ; Table 1). After baseline testing in an
unmedicated state, patients received dopamine agonist therapy and
were followed-up for 12 weeks [pramipexole: n = 10, mean dose at
follow-up: 4.5 mg/day, range 3.0–6.5 mg/day; ropinirole: n = 10,
mean dose at follow-up: 6.0 mg/day, range: 2.5–7.5 mg/day;
rotigotine: n = 6; 6 mg/24 h; levodopa equivalent dose (LED):
250 mg/day; Tomlinson et al., 2010]. After the 12-week follow-up
period, participants were re-evaluated. In the second sample, we
included 15 patients with recent-onset PD receiving L-DOPA mono-
therapy and 15 matched healthy controls (Table 2). We assessed the
second sample only once. The diagnosis of PD was based on the UK
Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria
(Hughes et al., 1992). All participants gave written informed consent
prior to their participation. All procedures were approved by the
Human Investigation Review Board (protocol number: 2697/2011) in
accordance with the declaration of Helsinki (1964).
Clinical and demographic assessment
Trained neurologists and clinical psychologists, who were blind
to diagnosis, attention test performance and medication status,
administered the scales and interviews. The severity of PD
.
What was the target letter?
GOOD ANSWER! 
Which scene was presented?
A or B? 
Scene with a black distractor letter 
Scene with a white target letter 
Fixation point (300 ms)
Trial
(rapid serial
presentation):
16 scenes 
133 ms/scene 
367 ms ISI
Task: remember 
the target letter, 
ignore the 
distractor
BA
Scene alone without letter 
K
F
Can you remember the distractor letter?
Post-trial questions:
1.
2.
3.
Fig. 1. Illustration of scene sequences. Two scenes appeared with white target letters that should be remembered, and two scenes appeared with black distractor
letters that should be ignored. Following the trial, participants ﬁrst typed the target letter, then the distractor letter and ﬁnally chose from the two test scenes.
Only the recall of the target letter was rewarded. ISI, inter-stimulus interval.
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symptoms was evaluated using the Hoehn–Yahr Scale (Hoehn &
Yahr, 1967) and the Uniﬁed Parkinson’s Disease Rating Scale (UP-
DRS; Lang & Fahn, 1989). For the diagnosis of possible mental dis-
orders, we used the Structured Clinical Interview for DSM-IV Axis
I Disorders, Clinician Version (First et al., 1996). Depressive symp-
toms, impulse control disorders and pathological gambling were
screened with the Hamilton Depression Rating Scale (HAM-D;
Hamilton, 1960), Minnesota Impulsive Disorders Interview (MIDI;
Christenson et al., 1994) and South Oaks Gambling Screen (SOGS;
Lesieur & Blume, 1987), respectively.
We also administered the Barratt Impulsiveness Scale-11 (BIS-11)
evaluating three dimensions of impulsivity (motor impulsivity, atten-
tional impulsivity and non-planning; Patton et al., 1995). Beyond
the total BIS-11 score, we focused on attentional impulsivity
because this dimension is the most deﬁnitive measure of impulsivity
in PD (Antonini et al., 2011), and this dimension of the BIS-11 is
the most relevant in relation to attentional functions.
Socioeconomic status was described with the Hollingshead Four-
Factor Index (Hollingshead, 1975), and general cognitive functions
were assessed with the revised version of the Wechsler Adult Intelli-
gence Scale (Wechsler, 1981).
Attentional boost test (ABT)
Stimuli were presented on a VP2765-LED-27″ monitor (ViewSonic,
Walnut, CA, USA; refresh rate: 60 Hz, resolution: 1920 9
1080 pixel; viewing distance: 50 cm; output luminance: 65 cd/m2)
controlled by a personal computer (Dell XPS workstation). We used
photographs of natural and urban scenes (size: 28º of visual angle), as
described previously (Levy-Gigi & Keri, 2012; Szamosi et al., 2013).
The experimental trials included rapid serial presentations of
scenes (exposure time: 133 ms/scene; inter-stimulus interval:
367 ms). Participants were presented with 16 scenes. Four of the 16
scenes contained superimposed letters in their center (two white tar-
get letters; two black distractor letters; Fig. 1). Twelve scenes in the
sequence contained no letters. The task was to remember the target
letters. Participants were explicitly instructed to ignore and forget
the distractor letters. Following each trial (presentation of 16 scenes:
two scenes with target; two scenes with distractor; and 12 scenes
alone in a pseudorandom order), participants were ﬁrst asked to type
the target letter, which was followed by immediate feedback (‘Good
answer!’ with a smiling cartoon face and a symbolic monetary
reward of 100 Hungarian Forints; wrong answers were not followed
by feedback). Following the response, we asked the participants to
type the distractor letter if they remembered that. Immediately after
the letter recall task, two scenes (‘A’ and ‘B’) were exposed for
3000 ms. One of these scenes was from the sequence (serial posi-
tion: 6–14). The other scene was not presented in the sequence.
The task was to decide which of the two scenes appeared in the
sequence by pressing one of two keys (‘A’ or ‘B’; Fig. 1). The
scene presented in this recognition phase could be a scene without a
letter, with a target letter, or with a distractor letter in the sequence.
In task introduction and instructions, it was emphasized that the
main aim of the game was to remember the target letter, which led
to reward. Recall of distractor letters and scene recognition were not
followed by feedback. There were 300 intermixed trials (10 blocks
of 30 trials) separated by breaks. Before the test, participants
received a training session (30 trials). However, they did not see the
test scenes before the rapid serial presentation trials. The dependent
Table 1. Clinical and demographic characteristics of the participants in the
follow-up study
Controls Parkinson’s disease (PD)
Number of participants
(male/female)
25 (18/7) 26 (17/9)
Age (years) 48.6 (6.5) 49.2 (7.4)
Education (years) 13.9 (7.4) 14.1 (6.6)
Full-scale IQ (WAIS-R) 105.4 (10.1) 104.6 (11.0)
Socioeconomic status
(Hollingshead)
35.6 (13.9) 35.5 (17.3)
Time since onset of ﬁrst
symptoms (months)
– 15.4 (7.4)
No. of patients in
Hoehn-Yahr Stage
– 1.0 : 4
1.5 : 13
2 : 9
UPDRS total
Baseline – 33.5 (5.2)
Follow-up – 30.2 (4.6)*
UPDRS III (motor)
Baseline – 25.1 (5.0)
Follow-up – 21.6 (5.4)†
HAM-D
Baseline 3.5 (2.5) 5.7 (4.2)
Follow-up 3.8 (2.3) 2.6 (2.2)‡
BIS-11
Total score
Baseline 62.4 (9.8) 60.7 (10.9)
Follow-up 62.5 (9.5) 64.1 (12.0)§
Attentional score
Baseline 16.7 (3.9) 15.5 (3.4)
Follow-up 16.9 (3.8) 17.0 (3.3)¶
Data are mean (standard deviation). BIS-11, Barrett Impulsiveness Scale-11;
HAM-D, Hamilton Depression Scale; UPDRS, Uniﬁed Parkinson’s Disease
Rating Scale; WAIS-R, Wechsler Adult Intelligence Scale, revised. The two
groups did not differ in gender distribution, age, education, IQ, and socioeco-
nomic status (chi-square and t-test, P > 0.5). *t50 = 2.50, P = 0.02 (baseline
vs. follow-up). †t50 = 2.39, P = 0.02 (baseline vs. follow-up).
‡PD[base-
line] > control[baseline]; PD[baseline]>PD[follow-up]. §PD[follow-up]>PD
[baseline]. ¶PD[follow-up] > PD[baseline](all analyses in c-f: ANOVA followed
by Tukey HSD, P < 0.05).
Table 2. Clinical and demographic characteristics of the participants in the
replication study
Controls Parkinson’s disease (PD)
Number of participants
(male/female)
15 (10/5) 15 (9/6)
Age (years) 59.4 (7.0) 60.4 (4.1)
Education (years) 14.6 (4.4) 14.2 (4.9)
Full-scale IQ (WAIS-R) 110.6 (10.8) 109.4 (12.3)
Socioeconomic status
(Hollingshead)
39.4 (12.0) 40.1 (13.8)
Time since onset of ﬁrst
symptoms (months)
– 30.6 (8.5)
No. of patients in
Hoehn-Yahr Stage
– 1.0 : 1
1.5 : 5
2 : 9
L-DOPA (mg/day) – 690.0 (365.7)
UPDRS total 36.7 (6.9)
UPDRS III (motor) 29.5 (7.2)
HAM-D 3.5 (2.3) 7.3 (3.8)*
BIS-11
Total score 60.3 (9.6) 62.1 (7.9)
Attentional scores 15.7 (3.8) 16.9 (3.9)
Data are mean (standard deviation) with the exception of gender. BIS-11,
Barrett Impulsiveness Scale -11; HAM-D, Hamilton Depression Scale;
UPDRS, Uniﬁed Parkinson’s Disease Rating Scale; WAIS-R, Wechsler Adult
Intelligence Scale, revised. The two groups did not differ in gender distribu-
tion, age, education, IQ, and socioeconomic status (chi-square and t-test,
P > 0.5). *t28 = 3.32, P = 0.003.
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measures were the percentage of correctly recalled letters and the
percentage of correctly recognized scenes.
The task described above was different from the original proce-
dure used by Lin et al. (2010): (i) correct responses in the letter
recall phase were rewarded; (ii) two scenes had white (target) and
two scenes black (distractor) letters during the 16-item serial visual
presentation stream; (iii) participants completed a recall task for both
target and distractor letters. However, participants were asked to
ignore, suppress and not remember the distractors, which is similar
to directed forgetting paradigms (Baddeley et al., 2009).
Attention network test (ANT)
The method has been extensively documented in previous studies
(Fan et al., 2002, 2005, 2009). The ANT has been used in many
studies on the genetics, development and clinical disorders of atten-
tion (e.g. Posner, 2008). The test–retest reliability of the ANT was
adequate in healthy individuals and patients with schizophrenia
(Hahn et al., 2011). We used this procedure in the present study.
The apparatus for stimulus presentation and response collection was
the same as in the ABT.
The experimental trials consisted of the following parts: (i) ﬁrst
ﬁxation (duration: 400–1600 ms); (ii) cue presentation (duration:
100 ms); (iii) second ﬁxation (duration: 400 ms); (iv) target presen-
tation (maximum duration: 1700 ms). The target stimulus consisted
of ﬁve horizontal arrows or lines presented above or below the ﬁxa-
tion cross. We asked the participants to indicate the direction of the
central arrow by pressing keys representing left or right direction on
the computer keyboard. Flankers next to the central arrow were lines
(neutral target condition) or arrows with the same (compatible) or
opposite (incompatible/conﬂict) direction. The cue stimuli could be
a spatial cue (presented above or below the ﬁxation cross indicating
the location of the target), a double cue (presented above and below
the center) and a center cue (presented in the center). There were
trials with no cues.
First, participants received 24 training trials with feedback.
Second, we presented 288 trials (4 cues 9 3 targets 9 8 repetitions
per block 9 3 blocks). The sequence of trials was pseudo-random-
ized. There was no feedback. The dependent measures were
response time and error rate differences reﬂecting the alerting,
orienting and executive components of attention. These indexes
were calculated as follows: alerting–no cue minus double cue;
orienting–previous center cue minus previous spatial cue; executive
(conﬂict)–incompatible targets minus targets.
Statistical analysis
We used STATISTICA 11 (StatSoft, Tulsa, USA) and Prism 6 (Graph-
Pad, La Jolla, USA) software for data analysis. First, we ran good-
ness-of-ﬁt analysis (Kolmogorov–Smirnov test for normality of data
distribution). We used repeated measures analyses of variance (ANO-
VAs), followed by Tukey Honestly Signiﬁcant Difference (HSD) post
hoc tests. In the analysis of the letter recall part of the ABT, the
between-subjects factor was group (PD vs. controls) and the within-
subjects factors were time (baseline vs. follow-up) and stimulus type
(target vs. distractor letters). In the analysis of the scene recognition
part of the ABT, the between-subjects factor was group (PD vs.
controls), and the within-subjects factors were time (baseline vs.
follow-up) and stimulus type (scenes associated with targets, distrac-
tors and scenes alone). In the ANT, we ran separate ANOVAs for
mean response time and error rate, response time indexes, and error
rate indexes with the group as the between-subjects factor and time
as the within-subjects factor. The same ANOVA design was used for
the analysis of rating scales (HAM-D and BIS-11). In the replication
sample, time was not a within-subjects factor because it was a
cross-sectional study. To explore the relationship between changes
in ABT and rating scales, we calculated Pearson’s product moment
correlation coefﬁcients, corrected for multiple comparisons with the
Bonferroni method. Demographic parameters were compared with
two-tailed t-tests and chi-square tests. The level of statistical signiﬁ-
cance was a < 0.05.
Results
General description of the sample from the follow-up study
Table 1 depicts the clinical and demographic characteristics of the
patients with PD and control individuals. One patient with PD had
speciﬁc phobia. None of the other patients and controls exhibited
DSM-IV Axis I disorders at baseline and follow-up. MIDI/SOGS
revealed no impulse control disorders at baseline and follow-up.
Patients with PD and control individuals did not differ in age,
gender, education, IQ and socioeconomic status. Patients with PD
scored higher than controls on the HAM-D scale at baseline but not
at follow-up. Patients with PD and controls did not differ signiﬁ-
cantly in BIS-11 scores, although patients with PD achieved higher
scores at follow-up relative to baseline (Table 1).
Detection of target and distractor letters
Patients with PD and control volunteers displayed similar letter
detection performances at baseline and follow-up (ANOVA, P > 0.5).
As expected, letter detection performance for targets was higher than
that for distractors (P < 0.0001; Fig. 2).
ABT
Figure 3 depicts the results from the scene recognition test. The ANOVA
revealed signiﬁcant main effects of group (F1,49 = 7.0, P < 0.05,
g2 = 0.13), time (F1,49 = 40.06, P < 0.0001, g
2 = 0.45) and stimulus
type (F2,98 = 233.66, P < 0.0001, g
2 = 0.83). There were signiﬁcant
two-way interactions between group and time (F1,49 = 33.50, P <
0.0001, g2 = 0.41), group and stimulus type (F2,98 = 3.55, P < 0.05,
g2 = 0.07), and time and stimulus type (F2,98 = 6.74, P < 0.005,
g2 = 0.12). We also found a three-way interaction among group, time
and stimulus type (F2,98 = 7.75, P < 0.005, g
2 = 0.14). A control
analysis indicated no signiﬁcant differences among patients receiving
different dopamine agonists (F < 1, P > 0.5).
Fig. 2. Letter recall performance in Parkinson’s disease (PD) and healthy
control individuals (CONT) at baseline (1) and follow-up (2). There was no
signiﬁcant difference between the two groups. Error bars indicate SDs.
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Tukey HSD tests yielded no difference between patients with PD
and control individuals at baseline (P > 0.5). At follow-up, patients
with PD showed higher levels of scene recognition performance
relative to control individuals when distractors and targets were
presented with the scenes in the trial sequence (P < 0.001 and
P < 0.05, respectively). Within-group comparisons revealed good
test–retest characteristics in control individuals (baseline vs. follow-
up: P > 0.5; correlations: r > 0.7). In PD, we observed enhanced
scene recognition performances at follow-up relative to baseline
when scenes were presented with targets and distractors (P < 0.01),
but not when scenes were presented alone in the trial sequence
(P > 0.5; Fig. 3). There was a signiﬁcant positive relationship
between recognition improvements for scenes presented with targets
and distractors in the trial sequence (r = 0.72, P < 0.001). In
patients with PD, there was no signiﬁcant correlation between the
recall of distractor letters and the recognition of scenes paired with
distractors (r = 0.16).
ANT
The ANOVA conducted on the mean response time indicated signiﬁ-
cant main effects of group (F1,49 = 14.73, P < 0.001, g
2 = 0.23)
and time (F1,49 = 10.37, P < 0.005, g
2 = 0.17). The interaction
between group and time was also signiﬁcant (F1,49 = 7.53,
P < 0.05, g2 = 0.13). The post hoc analysis conﬁrmed that patients
with PD responded slower than controls at baseline (P < 0.0001)
and follow-up (P < 0.05). Within-group comparisons revealed that
in PD the response time was faster at follow-up relative to baseline
(P < 0.005), whereas in control volunteers response latency showed
a marked stability over time (baseline vs. follow-up, P = 0.98).
Other measures of the ANT did not show signiﬁcant alterations in
PD compared with control individuals (P > 0.1; Figs 4 and 5).
There were no signiﬁcant correlations between ANT and ABT mea-
sures (0.2 < r < 0.2, P > 0.1).
Correlation between changes in clinical scales and ABT
We calculated correlation coefﬁcients between changes in UPDRS,
HAM-D and BIS-11 attention scores and changes in scene recognition
when scenes were presented with targets and distractors (change: fol-
low-up–baseline). Given that this analysis was exploratory, we used
Bonferroni corrections for multiple comparisons. We found signiﬁcant
correlation between changes in BIS-11 attention scores and changes in
recognition performance for distractor-associated scenes (r = 0.66,
P < 0.001; other correlations: 0.4 < r < 0.4, P > 0.05). LED did
not correlate with BIS-11 and attentional boost (0.3 < r < 0.3,
P > 0.1).
Replication in patients with PD receiving L-DOPA
Table 2 summarizes the characteristics of the replication sample.
Patients with PD and controls were matched for demographic
parameters. Two patients with PD had DSM-IV major depressive
disorder, and one patient had generalized anxiety disorder. No
impulse controls disorders were diagnosed. Patients with PD
displayed higher scores than control individuals on HAM-D
(Table 2).
Patients with PD and control individuals performed similarly on
the letter detection task [patients with PD–target: 93.2% (SD = 3.2),
distractor: 61.3% (SD = 4.6); controls–target: 93.3% (SD = 3.1),
distractor: 61.6% (SD = 5.6); P > 0.5].
The ANOVA conducted on the scene recognition performance
revealed signiﬁcant main effects of group (F1,28 = 35.73, P < 0.0001,
g2 = 0.56) and stimulus type (F2,56 = 63.16, P < 0.0001, g
2 = 0.69).
The two-way interaction between group and stimulus type was signiﬁ-
cant (F2,56 = 4.93, P < 0.05, g
2 = 0.15). Tukey HSD tests indicated
that patients with PD showed higher levels of scene recognition than
control individuals when scenes were presented with targets and
distractors in the trial sequence (P < 0.01; Fig. 6).
We calculated correlations between scene recognition, HAM-D,
UPDRS and BIS-11 attention score. In the whole sample (n = 30),
we found a signiﬁcant positive correlation between BIS-11 attention
Fig. 3. Recognition performance for scenes presented alone, with distractor
letters, and with target letters in Parkinson’s disease (PD) and healthy control
individuals (CONT) at baseline (1) and follow-up (2). At follow-up, patients
with PD receiving dopamine agonists outperformed control individuals for
scenes with targets (*P < 0.05, Tukey HSD test) and scenes with distractors
(**P < 0.001, Tukey HSD test). Error bars indicate SDs.
Fig. 4. Mean response time and index values from the attention network test
(ANT). Patients with Parkinson’s disease (PD) responded slower than control
individuals (CONT) at baseline (1) (**P < 0.0001, Tukey HSD test) and fol-
low-up (2) (*P < 0.05, Tukey HSD test). There were no signiﬁcant differ-
ences in index values (alerting, orienting, conﬂict). Error bars indicate SDs.
Fig. 5. Mean error rates (%) from the attention network test (ANT). There
were no statistically signiﬁcant differences between patients with Parkinson’s
disease (PD) and control individuals (CONT). Error bars indicate SDs.
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score and recognition performance for distractor-associated scenes
(r = 0.41, P = 0.02).
Discussion
Summary of the results
We observed no evidence for attentional dysfunctions in drug-naïve,
young patients with PD. However, at follow-up when patients with
PD received dopamine agonists, we found enhanced attentional
boost for both target- and distractor-associated scenes: patients with
PD recognized scenes better than control individuals did when
scenes were presented with either targets or distractors in the encod-
ing phase. Higher impulsive attention was associated with better
scene recognition performance when scenes were presented with
distractors in the encoding phase. This ﬁnding is against the hypoth-
esis that dopamine selectively enhances memory for reward/target-
associated background information. Instead, dopamine enhances
attentional impulsivity and facilitates memory for information
presented with both targets and distractors. However, there was a
speciﬁc association between attentional impulsivity and distractor-
associated recognition performance. Dopamine agonists and L-DOPA
had no general enhancing effect on memory because recognition
memory for scenes presented alone was not encouraged.
Enhanced attentional boost was not related to the alerting, orient-
ing or executive components of attention, which were not affected
by dopaminergic medications. We replicated enhanced attentional
boost in elderly patients with PD who received L-DOPA. Despite
the differences in patient characteristics and design, the results were
consistent in the two PD groups.
Mechanisms of attentional boost
Swallow & Jiang (2011) delineated several hypotheses to explain
the attentional boost effect. The ﬁrst is attentional cueing, which is
based on an orienting response to the target leading to a concur-
rently enhanced processing of the background scene. Attentional
cueing may occur concurrently with perceptual learning when target
and scene are assembled into a single object (Driver & Baylis,
1989). Based on our ﬁndings, however, a simple attentional cueing
does not sufﬁciently explain attentional boost because we did not
ﬁnd any connection with alerting and orienting of visual attention.
In a similar paradigm to that used in the present study, Leclercq &
Seitz (2012) found poor memorization for scenes that were preceded
by an auditory alerting cue. However, for target-paired scenes,
memory was enhanced when an alerting cue preceded the target, but
only when the cue was available only on a subset of trials (Leclercq
& Seitz, 2012).
Another possibility is that the target elicits a reward/salience
signal because the proper identiﬁcation and recall of the target letter
was the main purpose of the task, and therefore it was indirectly
reinforced in the experimental conditions (Seitz & Watanabe, 2009;
Swallow & Jiang, 2011; but see also Tosoni et al., 2013). In the
present study, we used a direct reward. This reward might ‘widen
the window of attention’ facilitating the encoding of the background
scene. The hippocampal formation may play a pivotal role in this
encoding process because individuals with hippocampal atrophy had
weak attentional boost (Szamosi et al., 2013). Shohamy & Wagner
(2008) showed that the interaction between midbrain dopaminergic
centers (ventral tegmental area/substantia nigra) and the hippocampal
formation is essential for associative encoding (see also Wimmer
et al., 2012). There is evidence that in the hippocampus dopaminer-
gic modulation of attention is important in the selection of relevant
and salient information (Muzzio et al., 2009). We propose that simi-
lar mechanisms may be implicated in attentional boost, which is
intact in early-stage PD when dopaminergic loss is not pronounced
in the midbrain-hippocampal system (Foerde et al., 2013). If dopa-
minergic medications are used in this stage of the disease, patients
will demonstrate enhanced attentional boost outperforming healthy
unmedicated individuals.
An intriguing ﬁnding was that patients with PD receiving dopami-
nergic medications displayed enhanced attentional boost not only in
the case of rewarded targets, but also in the case of distractors. In
other words, they might encode scenes not only at behaviorally
rewarded points of time, but also at behaviorally inhibited occasions
when central stimuli (distractors) had to be ignored. In contrast, at
behaviorally neutral points (scenes alone), there were no such
effects. Moreover, patients with PD successfully ignored the distrac-
tors, and yet they had increased levels of recognition for scenes
exposed concurrently with the omitted distractors, suggesting that
they failed to ‘close the window of attention’ spreading to the back-
ground scene. In a different paradigm, Cools et al. (2010) also
revealed that dopaminergic medications decreased ‘distractor resis-
tance’ in PD (see also Moustafa et al., 2008).
Dopamine, attention and PD
The results of the present study are consistent with the ﬁndings of
previous reports that found no severe attentional dysfunction in
early-stage PD (e.g. Rafal et al., 1984; Della Sala et al., 1986;
Cossa et al., 1989; Lee et al., 1999; Kingstone et al., 2002; Koerts
et al., 2009; Cristinzio et al., 2012), and indicate that dopamine
agonists do not affect alerting, orienting and executive attention.
Other researchers suggested that attentional dysfunction in PD is
conﬁned to internal cognitive control mechanisms (Brown &
Marsden, 1988; Bennett et al., 1995). However, using the ANT,
Zhou et al. (2012) demonstrated a selective deﬁcit of the orienting
network, although results also revealed that alerting and executive
components might be compromised in a more advanced stage of the
disease (see also Allcock et al., 2009; Vandenbossche et al., 2012).
Results from animal models and human pharmacological studies
suggest that dopamine is speciﬁcally related to the executive atten-
tional network (Marrocco & Davidson, 1998). However, Robbins
(2002) argued that in animals the systematic administration of
dopaminergic agents predominantly affects response latency,
premature responses and omissions via the dorsal and ventral
striatal systems. The administration of dopamine agonists in
Fig. 6. Recognition performance for scenes presented alone, with distractor
letters, and with target letters in Parkinson’s disease (PD) receiving L-3,
4-dihydroxyphenylalanine (L-DOPA) and healthy control individuals
(CONT). Patients with PD outperformed controls for scenes with targets and
distractors (*P < 0.01, Tukey HSD test).
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humans also modulates striatal and midbrain responses to reward
(Riba et al., 2008; Abler et al., 2009). Our ﬁndings are consistent
with the response speed hypothesis of systematic dopaminergic
effects (Robbins, 2002) because the sole change after the adminis-
tration of dopamine agonists was shorter mean reaction times.
Dopamine agonists had no noticeable effects on the altering, ori-
enting and executive measures in contrast to attentional boost,
which was signiﬁcantly enhanced. This suggests that the attention
indexes, as measured by the ANT, are dissociable from attentional
boost.
Atypical attentional boost and impulsivity: relevance for
translational neuroscience
What is the practical relevance of enhanced attentional boost? We
found that changes in BIS-11 attentional impulsivity correlated with
atypical attentional boost (enhanced memory for distractor-associated
scenes). Housden et al. (2010) also reported impulsivity in medi-
cated patients with PD. In the ABT, target stimuli are salient and
rewarded, leading to the enhanced encoding of the background
scene. Distractors are not rewarded, and therefore there is no
enhanced encoding of the background scene. This latter omission of
distractor-associated scenes is disinhibited in patients with PD
receiving dopaminergic medications, which is in accordance with
our previous results from a simple associative learning task (Nagy
et al., 2012).
The widespread use of dopamine receptor agonists in PD drew
attention to the adverse psychological effects of these medications,
with a special reference to impulse control disorders (pathological
gambling, hypersexuality, compulsive buying and eating). In dopa-
mine dysregulation syndrome, which is typically observed when
short-acting and high-potency dopaminergic medications are used,
patients exhibit addictive drug seeking and consumption, elevated
mood, dyskinesias, and withdrawal symptoms (dysphoria and anxi-
ety in response to dose reduction; Weintraub & Nirenberg, 2013).
Researchers postulated that these adverse effects are related to the
mesencephalic-ventral striatal dopaminergic pathways, which are
essential in reward, motivation and mood regulation; speciﬁcally,
dopamine agonists may disrupt risk evaluation in the striatum in
patients with impulse control disorders (Lawrence et al., 2003;
Rao et al., 2010; Voon et al., 2011). This is also consistent with
the animal studies reviewed above (Robbins, 2002).
In our study, none of the patients developed impulsive-compul-
sive behavior, although we observed a signiﬁcant elevation of
BIS-11 scores after dopaminergic medications relative to the unmed-
icated baseline. This is consistent with the ﬁndings of Isaias et al.
(2008) who reported increased impulsivity in medicated patients
with PD. Antonini et al. (2011) showed a trend toward higher BIS-
11 attention impulsivity even in unmedicated patients with PD who
displayed clinically meaningful impulse control disorders before the
administration of dopaminergic medications. Canesi et al. (2012)
found no signiﬁcant difference in items of BIS-11 amongst groups
of patients with PD and control individuals, although BIS-11 score
positively correlated with LED and was numerically higher in medi-
cated patients with PD relative to control individuals. In the present
study, this correlation was not signiﬁcant, possibly because of the
small sample size and narrow range of doses.
Limitations and future directions
First, the sample size was too small to conduct powerful correlation
analyses taking into account all confounding and moderator
variables. Second, it is still unclear whether subtle changes in impul-
sivity are sufﬁcient to predict subsequent development of impulse
control disorders and dopamine dysregulation syndrome. We did not
assess patients with the above-mentioned clinical symptoms, but
high BIS-11 scores may be indicative for vulnerability to impulse
control disorders (Antonini et al., 2011).
The third potential limitation stems from the task design. Simulta-
neous instructions to ignore and then report the distractors may be
confusing, and makes them relevant and salient. Despite the fact that
the distractors were not rewarded, it is likely that they were selected
by contingent capture of attention (Folk et al., 1992), and then
intentionally forgotten or not reported. However, contingent capture
of attention facilitated scene memory only when patients with PD
received dopaminergic therapy, which, on the other hand, did not
affect intentional forgetting of distractors.
Our task was similar to directed forgetting designs (Baddeley
et al., 2009) when memory for ‘to-be-forgotten’ items is weaker,
but regularly above chance level. The above-chance level of per-
formance for distractor letters suggests reliable responses (i.e.
extreme below-chance performance might suggest that participants
intentionally did not report distractor letters that they remembered).
One may assume that participants simply knew that the distractor
will be asked and thus attempted to remember it better and with
it they encoded the scenes. However, our results do not indicate
that participants attempted to remember the distractor-associated
scenes better because scene recognition performance was at the
chance level in this condition, which was similar to the case when
scenes were presented alone. Moreover, in the dopamine replace-
ment condition, a boosting effect was observed for the recognition
of distractor-associated scenes but not for the recall of distractor
letters, which indicates an intriguing dissociation between the
recall of the central stimulus (letters) and the recognition of the
background information (scenes). A possible explanation may be
that the short-term memory systems responsible for maintaining
the letters and the neural systems responsible for the attentional
boost are not equally affected by PD and dopaminergic medica-
tions, and that medicated patients with PD have less control over
distracting items (e.g. Moustafa et al., 2008).
The neuronal correlates of attentional boost and its pharmacologi-
cal modulation need to be investigated using functional neuroimag-
ing methods. Swallow et al. (2012) provided evidence that
responding to target stimuli at behaviorally relevant points of time
enhanced activity in early visual cortical areas, but it is not clear
how it affects memory for contextual background images. Although
our current results and data from individuals with hippocampal atro-
phy (Szamosi et al., 2013) suggest the relevance of midbrain dopa-
minergic–hippocampal interactions in attentional boost (Shohamy &
Wagner, 2008; Wimmer et al., 2012), this hypothesis should be
directly tested.
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